Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
4
×
boston top stories
cancer
europe blog main
4
×
life sciences
national blog main
san francisco blog main
4
×
cancer drugs
eli lilly
europe top stories
indiana blog main
indiana top stories
national top stories
san francisco top stories
blueprint medicines
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
fda
national
new york blog main
new york top stories
novartis
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
allergan aesthetics
alzheimer's disease
amgen
What
drug
4
×
cancer
fda
medicines
acquisitions
address
approval
approves
biggest
bio
biotech
black
blueprint
build
buy
carries
ceo
certain
clinic
companies
company’s
daniel
debut
designed
diamond
dyne’s
eisai
eluded
flags
genetic
gilead
higher
hopes
incidence
ipo
latest
lead
leading
lines
lorcaserin
Language
unset
4
×
Current search:
drug
×
unset
×
" san francisco blog main "
×
" boston blog main "
×
" europe blog main "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
